,i  #aafth ,,congress  #ast ,session    
,h4 ,r4 #bcgf  ,,in ,,the ,,house ,,of  
,,representatives  ,april #bi1 #bjai,mr4
 ,collins of ,georgia 7for himself and  
,mr4 ,nadler7 introduced the following  
bill2 which was referred to the         
,committee on ,energy and ,commerce1 and
 in addition to the ,committee on the   
,judiciary1 for a period to be          
subsequently determined by the ,speaker1
 in each case for consideration of such 
provisions as fall within the           
jurisdiction of the committee concerned 
,a ,,bill  ,to require the ,federal     
,trade ,commission to study the role of 
intermediaries in the pharmaceutical    
supply chain and provide ,congress with 
appropriate policy recommendations1 and 
for other purposes4  #a4 ,short title   
,this ,act may be cited as the          
,prescription ,pricing for the ,people  
,act of #bjai4  #b4 ,definitions ,in    
this ,act3  7#a7 ,appropriate committees
 of congress ,the term appropriate      
committees of ,congress means-- 7,a7 the

 ,committee on the ,judiciary of the    
,senate2 and  7,b7 the ,committee on the
 ,judiciary of the ,house of            
,representatives4  7#b7 ,commission ,the
 term ,commission means the ,federal    
,trade ,commission4  #c4 ,study of      
pharmaceutical supply chain             
intermediaries and merger activity  7a7 
,initial report ,not later than #a year 
after the date of enactment of this     
,act1 the ,commission shall submit to   
the appropriate committees of ,congress 
a report that--  7#a7 addresses at      
minimum-- 7,a7 whether pharmacy benefit 
managers--  7i7 charge payers a higher  
price than the reimbursement rate at    
which the pharmacy benefit managers     
reimburse competing pharmacies2  7ii7   
steer patients for anticompetitive      
purposes to any pharmacies1 including   
retail1 mail-order1 or any other type of
 pharmacy1 in which the ,,pbm has an    
ownership interest2  7iii7 audit or     
review proprietary data1 including      
acquisition costs1 patient information1 

or dispensing information1 of competing 
pharmacies that can be used for         
anticompetitive purposes2 or  7iv7 use  
formulary designs to increase the market
 share of higher cost prescription drugs
 and depress the market share of lower  
cost prescription drugs 7each net of    
rebates and discounts72  7,b7 whether   
there are any specific legal or         
regulatory obstacles the ,commission    
currently faces in ensuring a           
competitive and transparent marketplace 
in the pharmaceutical supply chain1     
including the pharmacy benefit manager  
marketplace and pharmacy services       
administrative organizations2  7,c7 how 
companies and payers assess the         
benefits1 costs1 and risks of           
contracting with intermediaries1        
including pharmacy services             
administrative organizations1 and       
whether more information about the roles
 of intermediaries should be available  
to consumers and payers2 and  7,d7      
whether there are any specific legal or 

regulatory obstacles the ,commission    
currently faces in ensuring a           
competitive and transparent marketplace 
in the pharmaceutical supply chain1     
including the pharmacy benefit manager  
marketplace and pharmacy services       
administrative organizations2 and  7#b7 
provides-- 7,a7 observations or         
conclusions drawn from the ,november    
#bjag roundtable entitled ,understanding
 ,competition in ,prescription ,drug    
,markets3 ,entry and ,supply ,chain     
,dynamics1 and any similar efforts2     
7,b7 specific actions the ,commission   
intends to take as a result of the      
,november #bjag roundtable1 and any     
similar efforts1 including a detailed   
description of relevant forthcoming     
actions1 additional research or         
roundtable discussions1 consumer        
education efforts1 or enforcement       
actions2 and  7,c7 policy or legislative
 recommendations to-- 7i7 improve       
transparency and competition in the     
pharmaceutical supply chain2  7ii7      

prevent and deter anticompetitive       
behavior in the pharmaceutical supply   
chain2 and  7iii7 best ensure that      
consumers benefit from any cost savings 
or efficiencies that may result from    
mergers and consolidations4  7b7        
,interim report ,not later than #ahj    
days after the date of enactment of this
 ,act1 the ,commission shall submit to  
the appropriate committees of ,congress 
an interim report on the progress of the
 report required by subsection 7a71     
along with preliminary findings and     
conclusions based on information        
collected to that date4